MPS Ltd Q3 FY26 Earnings Analysis

Published 16 Aug 2026 | Market Cap: ₹4.9K Cr

Price

₹2,809

Market Cap

₹4.9K Cr

P/E Ratio

26.8

Earnings Summary

Unbound's revenues currently have over 60% contribution from North America; future growth will come predominantly from markets outside North America, with North America growing at single digits. MPS aims for 20%-25% year-on-year growth; PBT CAGR of 21% since FY’21. - Target revenue of INR 1500 crores at similar margins within a few years. - Growth driven by a blend of organic and inorganic strategies; acquisitions constitute ~60% of growth plan. - Segment revenue expected to evolve to approx.

📊 Revenue & Sales Performance

→Unbound's revenues currently have over 60% contribution from North America; future growth will come predominantly from markets outside North America, with North America growing at single digits.
→The company aims to double Unbound's revenue over the next few years by expanding into new geographies such as Southeast Asia, the Middle East, Europe, and Australia.
→The global healthcare AI and knowledge management market is projected to grow significantly, with the AI-driven knowledge management subsector expected to expand from $3 billion to $102 billion by 2034 at a 42% CAGR.
→MPS targets an overall growth rate of 20%-25% year-on-year, blending organic and inorganic routes, with acquisitions comprising about 60% of growth strategy.
→The revenue mix is expected to evolve to roughly 40% Research, 40% Education, and 20% Corporate Learning in the coming years.
→New cross-selling opportunities between MPS and Unbound customers are expected to accelerate revenue growth.

📈 Profitability & Margins

→MPS aims for 20%-25% year-on-year growth; PBT CAGR of 21% since FY’21.
→Target revenue of INR 1500 crores at similar margins within a few years.
→Growth driven by a blend of organic and inorganic strategies; acquisitions constitute ~60% of growth plan.
→Segment revenue expected to evolve to approx. 40% Research, 40% Education, 20% Corporate Learning.
→Unbound EBITDA margin expected to increase from 14% to early 20% in Q2 FY’27, then approach MPS average of ~30% by end of FY’27.
→Cross-selling and geographic expansion (outside North America) anticipated to drive revenue acceleration.
→Margin expansion through shared infrastructure and operational efficiencies.
→Dividend payout and capital distribution (dividends/buybacks) to continue as per Board’s discretion, factoring upcoming capital outflows and comfort with current debt levels.

🏗️ Capital Expenditure Plans

→MPS Limited expects significant capital outflow over the next 6 to 12 months related to current investments and acquisitions.
→The company shows an appetite for growth through acquisitions, with about 60% of its growth strategy relying on inorganic growth.
→Recent acquisitions like Unbound Medicine involve investments planned to grow the business significantly, including geographic expansion.
→MPS raised INR 42 crores of debt for the Unbound Medicine acquisition but remains comfortable with this debt level.
→Capital distribution through dividends or buybacks will continue if there is surplus capital and depending on board decisions, considering expected capital outflows.
→The company is focused on continued strategic investments in AI and technology to enhance product offerings, especially in Unbound, with ongoing AI infrastructure development and integration.
→Discussions on capital redistribution (dividends and buybacks) will continue at the board level in light of shareholder feedback.

💰 Fundraising & Capital Structure

→MPS Limited has raised INR 42 crores of debt related to the Unbound acquisition.
→The company is comfortable with this level of debt given their improved DSO (45 days).
→Rahul Arora mentioned that INR 100 to INR 200 crores of debt does not bother them.
→They do not believe in sitting on excess cash; any surplus capital not required for deployment in the next 6 to 12 months will be distributed via dividends or buybacks.
→No mention of any immediate future equity fundraising.
→Capital distribution decisions, including dividends and buybacks, will be discussed and decided at the board level.
→The current debt level is not viewed as a blocker for continuing capital distributions.

📋 Order Book & Pipeline

The transcript provided on pages 1 to 18 of the MPS Limited conference call dated February 18, 2026, does not explicitly mention the current or expected order book or pending orders. The discussion primarily focuses on: - The acquisition of Unbound Medicine, Inc., USA. - Synergies and growth strategy after acquisition. - EBITDA margins and revenue projections for Unbound. - Dividend and capital distribution policies. - Market expansion and cross-selling opportunities. - AI capabilities and product offerings. No specific details or figures related to existing order books or pending orders are shared in the transcript.

Key Metrics

Frequently Asked Questions

What were MPS Ltd Q3 FY26 results?

What is MPS Ltd share price analysis?

MPS Ltd currently shows a neutral. The stock trades at a P/E of 26.8 with a market cap of ₹4,916 Cr. Investors should review the full earnings analysis for detailed insights.

Is MPS Ltd planning capital expenditure?

MPS Limited expects significant capital outflow over the next 6 to 12 months related to current investments and acquisitions.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.